Skip Ribbon Commands
Skip to main content
Sign In

25679 Procollagen I Intact N-Terminal, Serum (PINP)

Procollagen I Intact N-Terminal, Serum (PINP)
Test Code: PINPSO
Test Components

​Procollagen I Intact N-Terminal

Useful For
​An aid in monitoring antiresorptive and anabolic therapy in patients with osteoporosis
 
An adjunct in the assessment of conditions associated with increased bone turnover such as Paget disease

This test should not be used as a screening test for osteoporosis in the general population.
Specimen Requirements
Specimen Type Preferred Container/Tube Acceptable Container/Tube Specimen Volume Specimen Minimum Volume
(allows for 1 repeat)
Pediatric Minimum Volume
(no repeat)
​Serum ​Red Top Tube (RTT) ​Serum Separator Tube (SST) ​0.5 mL ​0.25 mL
Collection Processing Instructions

​This test should not be requested in patients who have recently received radioisotopes, therapeutically or diagnostically, because of potential assay interference. A recommended time period before collection cannot be made because it will depend on the isotope administered, the dose given, and the clearance rate in the individual patient. Specimens will be screened for radioactivity prior to analysis. Radioactive specimens received in the laboratory will be held and assayed after the radioactivity has sufficiently decayed. This will result in a test delay.

Centrifuge and aliquot serum into a plastic vial.

Specimen Stability Information
Specimen Type Temperature Time
​Serum ​ ​ ​Frozen (preferred) ​180 days
​Ambient ​7 days
​Refrigerate ​7 days
Rejection Criteria
Gross Hemolysis
​Gross Lipemia
​Gross Icterus
Interference

There is diurnal variation of procollagen I intact N-terminal propeptide (PINP) levels, with the values being higher at night. When serial measurements of PINP are performed, specimens should be collected at the same time of the day.

PINP is metabolized in the liver. In individuals with severe liver disease, clearance from the circulation might be affected resulting in elevated PINP levels.

 In rare cases, some individuals can develop antibodies to mouse or other animal antibodies (often referred to as human anti-mouse antibodies [HAMA] or heterophile antibodies), which may cause interference in some immunoassays. Caution should be used in interpretation of results, and the laboratory should be alerted if the result does not correlate with the clinical presentation. 

Performing Laboratory Information
Performing Location Day(s) Test Performed Report Available
Methodology/Instrumentation
​Mayo Clinic Laboratories Tuesday, Thursday
​2-6 days
Radioimmunoassay (RIA)
Reference Lab
Test Information

​Procollagen type I propeptides are derived from collagen type I, which is the most common collagen type found in mineralized bone. In bone, collagen is synthesized by osteoblasts in the form of procollagen. This precursor contains a short signal sequence and terminal extension peptides: amino-terminal propeptide (PINP) and carboxy-terminal propeptide. These propeptide extensions are removed by specific proteinases before the collagen molecules form. Both propeptides can be found in the circulation and their concentration reflects the synthesis rate of collagen type I. Although collagen type I propeptides may also arise from other tissues (such as the skin, vessels, fibrocartilage, and tendons), most nonskeletal tissues exhibit a slower turnover than bone, and contribute very little to the circulating pool of PINP. PINP is considered the most sensitive marker of bone formation and it is particularly useful for monitoring bone formation therapies and antiresorptive therapies; it is recommended that the test be performed at baseline before starting osteoporosis therapy and performed again 3 to 6 months later.

Reference Range Information

Reference values have not been established for patients who are <18 years of age.

Adult male: 22-87 mcg/L

Adult female premenopausal: 19-83 mcg/L

Adult female postmenopausal: 16-96 mcg/L

Interpretation

This assay is specific for the intact trimeric form of procollagen type I N-terminal propeptide (PINP). When monitoring response to osteoporosis treatment, a change of greater or equal to 21% (least significant change) from baseline PINP levels (ie, prior to the start of therapy), 3 to 6 months after initiation of therapy indicates an adequate therapeutic response.

The direction of the change in PINP levels (decrease or increase) will depend on the type of osteoporosis treatment. In patients taking bisphosphonates, PINP levels have been shown to decrease up to 70% from baseline after 6 months of therapy. Treatment with hormone replacement therapy also shows a decrease in PINP levels but to a lesser degree than bisphosphonates therapy.

In patients treated with teriparatide (recombinant human parathyroid hormone 1-34), PINP levels increase from baseline, reflecting the stimulatory effect of teriparatide on osteoblasts and bone formation. PINP levels have been shown to significantly increase as early as 1 month after teriparatide treatment, peaking at 6 months following treatment. Increases greater than 10 mcg/L have been reported in 77% to 79% of teriparatide-treated patients after 3 months of therapy and are considered a successful response.

Outreach CPTs
CPT Modifier
(if needed)
Quantity Description Comments
​83519
Test Components

​Procollagen I Intact N-Terminal

Ordering Applications
Ordering Application Description

​Cerner
​Procollagen I Intact-N Terminal (PINP)​
If the ordering application you are looking for is not listed, contact your local laboratory for assistance.
Specimen Requirements
Specimen Type Preferred Container/Tube Acceptable Container/Tube Specimen Volume Specimen Minimum Volume
(allows for 1 repeat)
Pediatric Minimum Volume
(no repeat)
​Serum ​Red Top Tube (RTT) ​Serum Separator Tube (SST) ​0.5 mL ​0.25 mL
Collection Processing

​This test should not be requested in patients who have recently received radioisotopes, therapeutically or diagnostically, because of potential assay interference. A recommended time period before collection cannot be made because it will depend on the isotope administered, the dose given, and the clearance rate in the individual patient. Specimens will be screened for radioactivity prior to analysis. Radioactive specimens received in the laboratory will be held and assayed after the radioactivity has sufficiently decayed. This will result in a test delay.

Centrifuge and aliquot serum into a plastic vial.

Specimen Stability Information
Specimen Type Temperature Time
​Serum ​ ​ ​Frozen (preferred) ​180 days
​Ambient ​7 days
​Refrigerate ​7 days
Rejection Criteria
Gross Hemolysis
​Gross Lipemia
​Gross Icterus
Interference

There is diurnal variation of procollagen I intact N-terminal propeptide (PINP) levels, with the values being higher at night. When serial measurements of PINP are performed, specimens should be collected at the same time of the day.

PINP is metabolized in the liver. In individuals with severe liver disease, clearance from the circulation might be affected resulting in elevated PINP levels.

 In rare cases, some individuals can develop antibodies to mouse or other animal antibodies (often referred to as human anti-mouse antibodies [HAMA] or heterophile antibodies), which may cause interference in some immunoassays. Caution should be used in interpretation of results, and the laboratory should be alerted if the result does not correlate with the clinical presentation. 

Useful For
​An aid in monitoring antiresorptive and anabolic therapy in patients with osteoporosis
 
An adjunct in the assessment of conditions associated with increased bone turnover such as Paget disease

This test should not be used as a screening test for osteoporosis in the general population.
Test Components

​Procollagen I Intact N-Terminal

Reference Range Information

Reference values have not been established for patients who are <18 years of age.

Adult male: 22-87 mcg/L

Adult female premenopausal: 19-83 mcg/L

Adult female postmenopausal: 16-96 mcg/L

Interpretation

This assay is specific for the intact trimeric form of procollagen type I N-terminal propeptide (PINP). When monitoring response to osteoporosis treatment, a change of greater or equal to 21% (least significant change) from baseline PINP levels (ie, prior to the start of therapy), 3 to 6 months after initiation of therapy indicates an adequate therapeutic response.

The direction of the change in PINP levels (decrease or increase) will depend on the type of osteoporosis treatment. In patients taking bisphosphonates, PINP levels have been shown to decrease up to 70% from baseline after 6 months of therapy. Treatment with hormone replacement therapy also shows a decrease in PINP levels but to a lesser degree than bisphosphonates therapy.

In patients treated with teriparatide (recombinant human parathyroid hormone 1-34), PINP levels increase from baseline, reflecting the stimulatory effect of teriparatide on osteoblasts and bone formation. PINP levels have been shown to significantly increase as early as 1 month after teriparatide treatment, peaking at 6 months following treatment. Increases greater than 10 mcg/L have been reported in 77% to 79% of teriparatide-treated patients after 3 months of therapy and are considered a successful response.

For more information visit:
Performing Laboratory Information
Performing Location Day(s) Test Performed Report Available
Methodology/Instrumentation
​Mayo Clinic Laboratories Tuesday, Thursday
​2-6 days
Radioimmunoassay (RIA)
Reference Lab
For billing questions, see Contacts
Outreach CPTs
CPT Modifier
(if needed)
Quantity Description Comments
​83519
For most current information refer to the Marshfield Laboratory online reference manual.